X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Divis Laboratories Quarterly Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Divis Laboratories Quarterly Results   (DIVI)

Here are the latest quarterly results of Divis Laboratories. For more details, see the Divis Laboratories financial fact sheet and Divis Laboratories share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Divis Laboratories Quarterly Results

No. of Mths
Qtr. Ending
3
Sep-15
3
Dec-15
3
Mar-16
3
Jun-16
3
Sep-16
3
Dec-16
3
Mar-17
3
Jun-17
8-Qtr Chart
Click to enlarge
Net Sales Rs m9,6438,52910,95410,08110,0549,76510,6678,212 
Other income Rs m296152174163203185209297 
Turnover Rs m9,9408,68111,12710,24410,2579,95010,8768,509 
Expenses Rs m5,8835,3066,9746,0437,1425,9577,0475,764 
Gross profit Rs m3,7603,2233,9794,0382,9123,8083,6202,448 
Depreciation Rs m301299292301308310314323 
Interest Rs m3215444105 
Profit before tax Rs m3,7523,0743,8453,8962,8033,6793,5052,417 
Tax Rs m795608623878565996912652 
Profit after tax Rs m2,9572,4663,2223,0182,2392,6832,5931,765 
Gross profit margin %39.037.836.340.129.039.033.929.8 
Effective tax rate %21.219.816.222.520.227.126.027.0 
Net profit margin %30.728.929.429.922.327.524.321.5 
Diluted EPS Rs 11.1 9.3 12.1 11.4 8.4 10.1 9.8 6.7  
Diluted EPS (TTM) Rs 37.2 38.2 41.7 43.9 41.2 42.0 39.7 35.0  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

More Pharmaceuticals Company Quarterly Results:   MERCK LTD  INDRAPRASTHA MEDICAL  DISHMAN PHARMA  PFIZER  IPCA LABS  

Compare DIVIS LABORATORIES With:   MERCK LTD  INDRAPRASTHA MEDICAL  DISHMAN PHARMA  PFIZER  IPCA LABS  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 19, 2018 09:31 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - SUVEN LIFE COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS